REG - Evgen Pharma PLC - Appointment of Chief Executive Officer

Evgen PharmaAnnouncement

24/09/2020 07:00

RNS Number : 9223Z
  
Evgen Pharma PLC
  
24 September 2020
  
 

Evgen Pharma Plc
("Evgen" or "the Company")
 
Appointment of Chief Executive Officer
 
Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and other conditions, announces that Huw Jones PhD will be joining the Board as Chief Executive Officer in early October.
 
Dr Jones has over 30 years' experience of leadership roles in public and private R&D-based companies within the biotechnology and pharmaceutical sector, with a particular focus on pre-clinical and clinical drug development, dilutive and non-dilutive financing and business development. He is Chairman of Chronos Therapeutics Ltd, Non-Executive Director of Rexgenero Ltd and Strategic Advisor to Gen2 Neuroscience Ltd. Dr Jones holds a PhD in pharmacology from the University of Birmingham, UK.
 
Barry Clare, Chairman of Evgen commented: "The Board is delighted to appoint Huw as our new CEO as we work together to deliver the undoubted potential of SFX-01. We believe that SFX-01 has significant value across a range of diseases including cancer and respiratory diseases such as COVID-19."
 
Commenting on his appointment, Huw Jones said: "I am honoured to join the Board of Evgen at such an exciting time and to working with Board colleagues, management and partners to realise the promise of SFX-01. I've been impressed by the focus and commitment of my new colleagues and look forward to working with them towards providing a new treatment for patients with high unmet medical needs."
 
The following information regarding the appointment of Dr Huw Jones (aged 60) is required to be disclosed under Schedule 2(g) of the AIM Rules for Companies:
 



Current directorships and/or partnerships








Daffodil Consulting LLP








Chronos Therapeutics Limited








Rexgenero Limited

















In accordance with Schedule 2(g) v, Dr Jones was CEO of Ardana Plc at the time of its administration in June 2008.
There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014
Enquiries:
 



Evgen Pharma plc www.evgen.com 


via Walbrook 




Barry Clare, Chairman 








Richard Moulson, CFO 


















finnCap www.finncap.com 


+44 (0)20 7220 0500




Geoff Nash / Teddy Whiley (Corporate Finance) 








Alice Lane (ECM) 


















Walbrook PR 


+44 (0)20 7933 87870 or evgen@walbrookpr.com 




Paul McManus / Anna Dunphy 


+44 (0)7980 541 893 / +44 (0)7876 741 001 








About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
 
Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.
 
The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol EVG.  
For further information, please visit: www.evgen.com
For research on the Company, please visit: http://evgen.com/investors/analyst-coverage/
 
 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
BOAFLFVEAAIVFII